Newsletter

Pipeline, markets, policy, and science. Once a week.

You’re in. Check your inbox to confirm.

More stories

In depth

Ultomiris Is the Latest IgA Nephropathy Drug to Win on Proteinuria, Not Proof It Saves Kidneys

AstraZeneca's fifth Ultomiris indication arrives on a proteinuria surrogate, while the week-106 eGFR readout still decides whether the drug actually saves kidneys.

Read the story

Pipeline

See all
Neoclassical federal agency building exterior at dawn, symbolizing a regulatory safety decision
Policy

Why the FDA Put a Vision-Loss Warning on Every GLP-1 Label

The agency combed trials, real-world claims data, and case reports for two years before putting NAION on every GLP-1 label. The absolute risk is tiny, the relative signal is real, and the decision says a lot about how FDA weighs incomplete evidence.